Translational Development Acquisition Stock Price, News & Analysis
Company Description
Translational Development Acquisition (NASDAQ: TDAC) is a publicly traded shell companies company in the Blank Checks sector. The company has a market capitalization of $234.8M, ranking #4,485 among all listed U.S. companies by market cap.
TDAC stock has gained 4.6% over the past year, placing it at #2,233 in year-to-date performance among tracked companies. Shares last traded at $10.72.
On a trailing twelve-month basis, Translational Development Acquisition reported net income of $6.4M.
This page provides a comprehensive overview of TDAC stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Translational Development Acquisition (TDAC) stock last traded at $10.72, up 0.19% from the previous close. Over the past 12 months, the stock has gained 4.6%. At a market capitalization of $234.8M, TDAC is classified as a micro-cap stock with approximately 21.9M shares outstanding.
TDAC Rankings
Latest News
Translational Development Acquisition has 9 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 4 with negative movement. Key topics include acquisition. View all TDAC news →
SEC Filings
Translational Development Acquisition has filed 5 recent SEC filings, including 2 Form 425, 1 Form 4, 1 Form 8-K, 1 Form SCHEDULE 13G. The most recent filing was submitted on June 12, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all TDAC SEC filings →
Insider Radar
Insider buying activity at Translational Development Acquisition over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
operating income reached -$945K, and net income was $6.4M. The company generated -$608K in operating cash flow. With a current ratio of 0.07, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Short interest in Translational Development Acquisition (TDAC) currently stands at 193 shares, down 60.8% from the previous reporting period, representing 0.0% of the float. Over the past 12 months, short interest has decreased by 84.4%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Translational Development Acquisition (TDAC) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 20.8 days.
TDAC Company Profile & Sector Positioning
Translational Development Acquisition (TDAC) operates in the Shell Companies industry within the broader Blank Checks sector and is listed on the NASDAQ. In monthly performance, the stock ranks #2,481 among all tracked companies.
Investors comparing TDAC often look at related companies in the same sector, including Real Asset Acquisition Corp (RAAQ), Helix Acqsn II (HLXB), Sanaby Health (SANB), Melar Acquisition Corp. I (MACI), and B Riley Principl (BRIV). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate TDAC's relative position within its industry.